===
EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification (news
with additional features)
2024-05-13 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Göttingen, Germany | May 13, 2024
Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification

. Sartorius selected as preferred partner for development and commercialization of integrated and
continuous biomanufacturing (ICB) platform
. Modular platform will combine highest flexibility with standardization
. ICB supports lower resource consumption and higher productivity, enabling more affordable patient care
and sustainable bioprocessing
. Collaboration demonstrates Sartorius' leading position in the field of process intensification
The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end
platform for integrated and continuous downstream bioprocessing. Selected as a preferred supplier, Sartorius will
contribute its engineering and manufacturing expertise to commercialize ICB platforms based on prototypes developed by
Sanofi. In return, Sanofi will grant Sartorius exclusive access to its know-how and patents related to the ICB
platform.
Sartorius is committing to the rapid development of hardware, consumables and process automation for diverse
applications and volumes from development to commercial scale. As part of the collaboration and license agreement,
Sartorius will exclusively commercialize the ICB platform offering to customers worldwide.
"Technological innovation is crucial for biopharmaceutical companies to significantly reduce the cost of drug
manufacturing - while improving the environmental footprint of their operations - and ultimately getting life-saving
drugs to patients faster. As the biologics landscape becomes more diverse, teaming up with Sanofi is an excellent basis
for developing a unique modular platform that combines flexibility with the advantages of intensified bioprocessing.
This collaboration will help Sartorius to further expand its position as a leading company in the field of integrated
and continuous bioprocessing," said Jan Schäfer, Head of Separation Systems at Sartorius.
Integrated continuous biomanufacturing is an advanced approach to the production of biopharmaceuticals. The concept
aims to maximize efficiency by enabling uninterrupted and steady materials flow, as opposed to traditional batch
methods, and by integrating multiple unit operations into a lean process setup. ICB reduces the overall process
footprint, leading to lower raw material and energy consumption, higher productivity, and less waste.
Sartorius offers a wide array of applications for process intensification in both upstream and downstream, ranging from
high-throughput tools for process development to scalable, flexible manufacturing solutions.
A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab Products & Services division focuses on laboratories
performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research
institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps
customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The
company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide.
Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company
generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers
around the globe.
Visit our newsroom and follow Sartorius on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 (0)551.308.4067
Leona.malorny@sartorius.com

Additional features:
File: 20240513_SAG_Media Release_Sartorius collaborates with Sanofi
2024-05-13 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      SARTORIUS AG 

Otto-Brenner-Straße 20
37079 Göttingen
Germany

Phone:        +49.(0)551-308.0 
Fax:          +49.(0)551-308.3289 
E-mail:       info@sartorius.com 
Internet:     www.sartorius.com 
ISIN:         DE0007165607, DE0007165631 
WKN:          716560 , 716563 
Indices:      DAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, 

Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1901531

End of News EQS News Service
===
1901531 2024-05-13 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1901531&application_name=news

END) Dow Jones Newswires

May 13, 2024 09:01 ET (13:01 GMT)